Zhu Jie, Hatton Diane
MedImmune, One MedImmune Way, Gaithersburg, MD, 20878, USA.
MedImmune, Milstein Building, Granta Park, Cambridge, CB21 6GH, UK.
Adv Biochem Eng Biotechnol. 2018;165:9-50. doi: 10.1007/10_2016_55.
There are an increasing number of recombinant antibodies and proteins in preclinical and clinical development for therapeutic applications. Mammalian expression systems are key to enabling the production of these molecules, and Chinese hamster ovary (CHO) cell platforms continue to be central to delivery of the stable cell lines required for large-scale production. Increasing pressure on timelines and efficiency, further innovation of molecular formats and the shift to new production systems are driving developments of these CHO cell line platforms. The availability of genome and transcriptome data coupled with advancing gene editing tools are increasing the ability to design and engineer CHO cell lines to meet these challenges. This chapter aims to give an overview of the developments in CHO expression systems and some of the associated technologies over the past few years.
用于治疗应用的临床前和临床开发中的重组抗体和蛋白质的数量正在不断增加。哺乳动物表达系统是生产这些分子的关键，而中国仓鼠卵巢（CHO）细胞平台仍然是大规模生产所需稳定细胞系的核心。时间线和效率方面的压力不断增加、分子形式的进一步创新以及向新生产系统的转变，正在推动这些CHO细胞系平台的发展。基因组和转录组数据的可用性以及先进的基因编辑工具，正提高设计和改造CHO细胞系以应对这些挑战的能力。本章旨在概述过去几年CHO表达系统及一些相关技术的发展情况。
